1. Transitioning Therapy in PAH: Practical Strategies and Considerations

2. Panelists

3. Program Goals

4. Case Study Initial Evaluation November 2015

5. Case Study Initial Evaluation November 2015 (cont)

6. Case Study January 2016

7. Case Study May 2016

8. REVEAL 6MWD

9. RHC Findings

11. Intermediate Risk

12. High Risk

13. Parenteral Therapy

14. Oral Options

17. Initiation of Riociguat

18. Demonstrated Benefit

19. Why Might Riociguat Be Effective When PDE5i Has Failed?

20. Transitioning to sGC Stimulator

21. NT-proBNP Levels: Transition to Riociguat

22. Patient Support and Education

23. RESPITE Trial Limitations

24. New Step in the Evolution of Management of PAH?

25. Importance of Optimizing Therapy

26. Systemic BP A Limiting Factor?

27. Continued Role for Parenteral Therapies

28. Concluding Remarks

29. Abbreviations

30. Abbreviations (cont)